Abstract | BACKGROUND: OBJECTIVE: METHODS: RESULTS:
Erdosteine is a thiol agent with a multifactorial mechanism of action, namely: mucolytic, antibacterial, antioxidant and anti-inflammatory activity. In the acute exacerbation of chronic bronchitis/ COPD, addition of erdosteine 300 mg twice a day for 7 - 10 days to standard treatment improves the symptoms and reduces the time of disease. In clinically stable COPD, long-term treatment is associated with a reduction in acute exacerbation and hospitalization rate and a significant improvement of quality of life. Erdosteine could be most beneficial in patients who have repeated, prolonged or severe exacerbations of COPD.
|
Authors | Maurizio Moretti |
Journal | Expert opinion on drug metabolism & toxicology
(Expert Opin Drug Metab Toxicol)
Vol. 5
Issue 3
Pg. 333-43
(Mar 2009)
ISSN: 1744-7607 [Electronic] England |
PMID | 19331595
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antioxidants
- Expectorants
- Thioglycolates
- Thiophenes
- erdosteine
|
Topics |
- Animals
- Antioxidants
(adverse effects, pharmacology, therapeutic use)
- Bronchitis
(drug therapy)
- Clinical Trials as Topic
- Expectorants
(adverse effects, pharmacology, therapeutic use)
- Humans
- Pulmonary Disease, Chronic Obstructive
(drug therapy, physiopathology)
- Quality of Life
- Severity of Illness Index
- Thioglycolates
(adverse effects, pharmacology, therapeutic use)
- Thiophenes
(adverse effects, pharmacology, therapeutic use)
|